Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats

Imanishi, Yukiko; Saito, Atsuhiro; Komoda, Hiroshi; Kitagawa-Sakakida, Satoru; Miyagawa, Shigeru; Kondoh, Haruhiko; Ichikawa, Hajime; Sawa, Yoshiki

doi:10.1016/j.yjmcc.2007.11.001

Cited by 116 publications

(97 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Following direct injection into an infarcted heart, the cells have been demonstrated to improve cardiac function (13,14), decrease fibrous tissue accumulation (15), and repair cardiac infarcts (16). BMSCs are easy to obtain and have a high transfection efficiency, and therefore are ideal for genetic engineering and clinical applications (17).…”

Section: Discussionmentioning

confidence: 99%

Bone marrow mesenchymal stem cells improve myocardial function in a swine model of acute myocardial infarction

Zhao

Liu

Kong

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract.The aim of the current study was to confirm the effect and elucidate the mechanism of bone marrow mesenchymal stem cells (BMSCs) in acute myocardial infarction (AMI). AMI was induced in mini-swine by ligating the left anterior descending coronary artery, and BMSCs (1x10 7 ) were injected via a sterile microinjection into the ischemic area. Six months postoperatively, electrocardiograph-gated single photon emission computed tomography revealed that the myocardial filling defect was reduced and the left ventricular ejection fraction was improved in the BMSC group compared with the control group (P<0.05). Histopathological examination indicated that, in the BMSC treatment group, the percentage of survived myocardial tissue and the vessel density were increased, and the percentage of apoptosis was decreased compared with controls (P<0.05). Reverse transcription-polymerase chain reaction results indicated that the expression levels of multiple inflammatory factors were significantly upregulated in the BMSC group compared with levels in the control group (P<0.05). In conclusion, the present study demonstrated that BMSC injection significantly improved cardiac function and reduced infarct size in six months, indicating that this method may be valuable for future study in clinical trials. IntroductionAccording to 2011 statistics, acute myocardial infarction (AMI) is one of the most prevalent causes of death and morbidity (1,2). Adult cardiomyocytes lack the capacity for regeneration, so scar tissue replaces lost myocardium following myocardial infarction, and this leads to cardiac remodeling with reduced left ventricular (LV) function (3). Cell therapy is a potential method for the regeneration and repair of myocardium and the improvement of myocardial function following ischemic injury (4). A number of cell types, including foetal Flk1 + CD34 + CD31 -bone marrow stem cells (BMSCs) have demonstrated cardiac regenerative capacity (5), however, the mechanism that stem cell transplantation utilizes in order to improve cardiac function following ischemic heart disease is unclear and there is little information available regarding the medium-and long-term effects. On the other hand, there exist a variety of transplantation methods, including local intramyocardial injection, intravenous injection, and intracoronary injection to the infarct zone (6). Intramyocardial injection of BMSCs has been demonstrated to be safe, and to lead to reverse remodeling and improved contractile ability of scarred areas (3,7). The mechanisms by which BMSCs reduce infarct size and improve cardiac function in animal models are complicated, involving engraftment, differentiation into functional cardiomyocytes and paracrine signaling (8,9). In the present study, fetal Flk1 + CD34 + CD31 -BMSCs were transplanted via intramyocardial injection of the mini-swine, then the myocardial function, stem cell migration and extent of survival in the myocardium was evaluated. The current study was therefore designed to determine the long-term (6-month) e...

show abstract

Section: Discussionmentioning

confidence: 99%

Bone marrow mesenchymal stem cells improve myocardial function in a swine model of acute myocardial infarction

Zhao

Liu

Kong

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…Many clinical trials using BMSCs for treatment of stroke, spinal cord injury, myocardial infarction and joint repair have been reported [22][23][24][25][26]. For the treatment of liver cirrhosis using BMSCs, there have been many animal experiments [27,28] and clinical trials [1,4,29].…”

Section: Discussionmentioning

confidence: 99%

Tracking of transplanted mesenchymal stem cells labeled with fluorescent magnetic nanoparticle in liver cirrhosis rat model with 3-T MRI

Kim

Shim

et al. 2010

Magnetic Resonance Imaging

View full text Add to dashboard Cite

“…Based on this theory, Imanishi et al introduced allogenic MSCs, which have low immunogenicity [75], to treat acute myocardial infarction and observed that they triggered the secretion of vascular endothelial growth factor (VEGF) and preserved cardiac performance, accompanied by angiogenesis [76]. This strategy has the advantage of being applicable to emergent cases in clinical settings, but the possible disadvantage of having no effect on chronic heart failure.…”

Section: Paracrine Effect Of Cytokines After Cellular Cardiomyoplastymentioning

confidence: 99%

From bench to bedside, work in cell-based myocardial regeneration therapy

Miyagawa

Sawa²

2014

JBiSE

Self Cite

View full text Add to dashboard Cite

In clinical cellular cardiomyoplasty, bone marrow cells and myoblasts are introduced mainly to ischemic cardiomyopathy tissue via several cell delivery systems, such as needle injection or catheter. These clinical studies have demonstrated the safety and feasibility of this technique, but its effectiveness for treating heart failure, especially in the long term, is still under discussion. Neither of these cell types can differentiate into cardiomyocytes; rather, they improve the failing heart mainly by the paracrine effects of some cytokines, such as Hepatocyte growth factor (HGF) and Vascular endothelial growth factor (VEGF). Thus, many researchers have a great interest in stem cells, which exist in bone marrow, circulating blood, atrium, and adipose tissue, and can differentiate into cardiomyocytes. Although several stem cells with the potential to differentiate into various cell types have been reported, few can differentiate into cardiomyocytes. Moreover, beating cells that can demonstrate synchronized contraction with native cardiomyocytes are critical for the complete repair of severe heart failure. Therefore, stem cells with a high differentiation capacity should be explored for the goal of completely repairing severely damaged myocardium. In this review, we summarize the clinical protocols and basic experiments for cellular cardiomyoplasty using bone marrow cells, myoblasts, and other stem cells.

show abstract

Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats

Cited by 116 publications

References 31 publications

Bone marrow mesenchymal stem cells improve myocardial function in a swine model of acute myocardial infarction

Bone marrow mesenchymal stem cells improve myocardial function in a swine model of acute myocardial infarction

Tracking of transplanted mesenchymal stem cells labeled with fluorescent magnetic nanoparticle in liver cirrhosis rat model with 3-T MRI

From bench to bedside, work in cell-based myocardial regeneration therapy

Contact Info

Product

Resources

About